Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 7/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.47 |
| ▸ | POLR1A | O95602 | 1/20 | 0.43 |
| ▸ | CKS1B | P61024 | 2/20 | 0.42 |
| ▸ | SKP1 | P63208 | 2/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24126160 | 0.87 | USP30 (0.52) | USP30GABRA5POLR1ACKS1BSKP1 | |
| SCHEMBL21880092 | 0.83 | USP30 (0.41) | USP30GABRA5POLR1APARP1ADORA2A | |
| SCHEMBL23930977 | 0.82 | USP30 (0.44) | USP30GABRA5POLR1APARP1ADORA2A | |
| SCHEMBL23930984 | 0.82 | USP30 (0.40) | USP30POLR1APARP1ADORA2AADORA2B | |
| SCHEMBL21879895 | 0.81 | USP30 (0.39) | USP30POLR1APARP1ADORA2AADORA2B | |
| SCHEMBL21879973 | 0.80 | USP30 (0.39) | USP30GABRA5POLR1APARP1ADORA2A | |
| SCHEMBL23930985 | 0.76 | CNR1 (0.35) | USP30CKS1BSKP1SKP2 | |
| SCHEMBL23931020 | 0.74 | GABRA5 (0.36) | USP30GABRA5POLR1APOLBPARP1 | |
| SCHEMBL120242 | 0.74 | USP30 (0.64) | USP30GABRA5POLR1APOLB | |
| SCHEMBL21880100 | 0.73 | USP30 (0.43) | USP30POLR1APARP1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181536-A1 | ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-06-15 | — | — | US | disclosed |
| US-20210395234-A1 | NOVEL INDAZOLE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO. LTD. (JP) | 2021-12-23 | — | — | US | disclosed |
| WO-2021215545-A1 | ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181536-A1 | ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C | KRAS, NRAS, HRAS | USP30 2736/4885GABRA5 4527/4885POLR1A 1606/4885 |
| US-20210395234-A1 | NOVEL INDAZOLE COMPOUND OR SALT THEREOF | HDAC11, RCOR3, BICRA | USP30 3681/4885GABRA5 1911/4885POLR1A 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.